317 related articles for article (PubMed ID: 26022792)
1. Contrast-enhanced ultrasound with perflubutane in the assessment of anti-angiogenic effects: early prediction of the anticancer activity of bevacizumab in a mouse xenografted model.
Watanabe R; Munemasa T; Matsumura M
Ultrasound Med Biol; 2015 Sep; 41(9):2497-505. PubMed ID: 26022792
[TBL] [Abstract][Full Text] [Related]
2. Compensatory angiogenesis and tumor refractoriness.
Gacche RN
Oncogenesis; 2015 Jun; 4(6):e153. PubMed ID: 26029827
[TBL] [Abstract][Full Text] [Related]
3. Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience.
Hasan S; Chen E; Lanciano R; Yang J; Hanlon A; Lamond J; Arrigo S; Ding W; Mikhail M; Ghaneie A; Brady L
Front Oncol; 2015; 5():106. PubMed ID: 26029663
[TBL] [Abstract][Full Text] [Related]
4. RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.
Cannon TL; Kokon MA; Shafqat S; Deeken JF
Curr Treat Options Oncol; 2015 Jul; 16(7):33. PubMed ID: 26050230
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies.
Battaglia L; Gallarate M; Peira E; Chirio D; Solazzi I; Giordano SM; Gigliotti CL; Riganti C; Dianzani C
Nanotechnology; 2015 Jan; 26(25):255102. PubMed ID: 26043866
[TBL] [Abstract][Full Text] [Related]
6. Primary brain tumors and posterior reversible encephalopathy syndrome.
Kamiya-Matsuoka C; Cachia D; Olar A; Armstrong TS; Gilbert MR
Neurooncol Pract; 2014 Dec; 1(4):184-190. PubMed ID: 26034631
[TBL] [Abstract][Full Text] [Related]
7. Posterior Reversible Encephalopathy Syndrome in Patients With Cancer.
Singer S; Grommes C; Reiner AS; Rosenblum MK; DeAngelis LM
Oncologist; 2015 Jul; 20(7):806-11. PubMed ID: 26032137
[TBL] [Abstract][Full Text] [Related]
8. KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials.
Ying M; Zhu XX; Zhao Y; Li DH; Chen LH
Asian Pac J Cancer Prev; 2015; 16(10):4439-45. PubMed ID: 26028111
[TBL] [Abstract][Full Text] [Related]
9. Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Peters KB; Lou E; Desjardins A; Reardon DA; Lipp ES; Miller E; Herndon JE; McSherry F; Friedman HS; Vredenburgh JJ
Oncologist; 2015 Jul; 20(7):727-8. PubMed ID: 26025933
[TBL] [Abstract][Full Text] [Related]
10. Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.
Back M; Gzell CE; Kastelan M; Guo L; Wheeler HR
Neurooncol Pract; 2015 Mar; 2(1):48-53. PubMed ID: 26034641
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Sepúlveda JM; Belda-Iniesta C; Gil-Gil M; Pérez-Segura P; Berrocal A; Reynés G; Gallego O; Capellades J; Ordoñez JM; La Orden B; Balañá C
Clin Transl Oncol; 2015 Sep; 17(9):743-50. PubMed ID: 26033428
[TBL] [Abstract][Full Text] [Related]
12. Limited advances in therapy of glioblastoma trigger re-consideration of research policy.
Frosina G
Crit Rev Oncol Hematol; 2015 Nov; 96(2):257-61. PubMed ID: 26052048
[TBL] [Abstract][Full Text] [Related]
13. Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience.
Marino A; Caliolo C; Sponziello F; Nacci A; Quaranta A; Mazzoni E; Lutrino SE; Rizzo P; Calvani N; Orlando L; Schiavone P; Fedele P; D'Amico M; Chetrì MC; Cinefra M; Ferrara P; Cinieri S
Tumori; 2015; 101(5):524-8. PubMed ID: 26045117
[TBL] [Abstract][Full Text] [Related]
14. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.
Generali D; Venturini S; Rognoni C; Ciani O; Pusztai L; Loi S; Jerusalem G; Bottini A; Tarricone R
Breast Cancer Res Treat; 2015 Jul; 152(1):95-117. PubMed ID: 26044370
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal Vascular Endothelial Growth Factor: A Prognostic Factor and the Potential for Intraperitoneal Bevacizumab Use in Peritoneal Surface Malignancies.
Chia CS; Glehen O; Bakrin N; Decullier E; You B; Gilly FN; Passot G
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S880-7. PubMed ID: 26040606
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer.
Fu Y; Hu J; Du N; Jiao S; Li F; Li X; Ma J; Zhao H; Kang H
J Chemother; 2016 Jun; 28(3):218-24. PubMed ID: 26038980
[TBL] [Abstract][Full Text] [Related]
17. Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.
Sassier M; Dugué AE; Clarisse B; Lesueur P; Avrillon V; Bizieux-Thaminy A; Auliac JB; Kaluzinski L; Tillon J; Robinet G; Le Caer H; Monnet I; Madroszyk A; Boza G; Falchero L; Fournel P; Egenod T; Toffart AC; Leiber N; Do P; Gervais R
Lung Cancer; 2015 Aug; 89(2):161-6. PubMed ID: 26037036
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab.
Al-Shamsi HO; Al Farsi A; Anjum M; Shen H; Zbuk K; Cook RJ; Linkins LA; Major P
J Gastrointest Oncol; 2015 Jun; 6(3):274-9. PubMed ID: 26029454
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
Kocakova I; Melichar B; Kocak I; Bortlicek Z; Büchler T; Dusek L; Petruzelka L; Kohoutek M; Prausová J; Finek J; Mohelnikova-Duchonova B; Vyzula R
Anticancer Res; 2015 Jun; 35(6):3455-61. PubMed ID: 26026110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
